Clinical Trial Update: Cardioprotective Effects of Endogenous Erythropoietin in Patients Undergoing Coronary Artery Bypass Surgery [NA]

View source ↗

Summary

This completed clinical trial evaluated whether endogenous erythropoietin offers cardioprotection in patients undergoing coronary artery bypass grafting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Ischemic Heart Disease

Drugs mentioned

• Erythropoietin (erythropoietin)

Snippet

Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Conditions: Cardiac Surgery | NA | Status: COMPLETED